The “Respiratory Syncytial Virus Infections – Pipeline Insight, 2021” drug pipelines have been added to ResearchAndMarkets.com’s offering.
This “Respiratory syncytial virus infections – Pipeline Insight, 2021” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Respiratory syncytial virus infections pipeline landscape.
It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Respiratory syncytial virus infections R&D. The therapies under development are focused on novel approaches to treat/improve Respiratory syncytial virus infections.
Respiratory syncytial virus infections Emerging Drugs Chapters
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
This segment of the Respiratory syncytial virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Respiratory syncytial virus infections Emerging Drugs
GSK3844766A: GlaxoSmithKline
This candidate vaccine contains a recombinant subunit pre-fusion RSV antigen (RSVPreF3) combined with GSK’s proprietary AS01 adjuvant, which is also used in GSK’s shingles vaccine. Currently, it is in phase III of the development stage for the treatment of Respiratory syncytial virus infections.
Nirsevimab (MEDI-8897): MedImmune
MEDI8897 is a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by a respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children. Currently, it is in phase III of the development stage.
Sisunatovir: ReViral
Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Preclinical tests showed sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir showed excellent exposure with no serious adverse events being reported.
In 2018, results from a Phase 2a challenge study in healthy adult volunteers were reported in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. ReViral has initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations
Respiratory syncytial virus infections: Therapeutic Assessment
This segment of the report provides insights about the different Respiratory syncytial virus infections drugs segregated based on the following parameters that define the scope of the report, such:
Major Players in Respiratory syncytial virus infections
There are approx. 50+ key companies are developing therapies for Respiratory syncytial virus infections. The companies which have their Respiratory syncytial virus infections drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.
Source: Businesswire